Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Biomea Fusion, Inc. Common Stock

BMEA

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Last trade $0.4901
Day change -$0.03 (-5.77%)
Day range $0.482 – $0.565
Volume 703,580
Market cap $38M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$37.79M
Price / earnings
—
Price / book
4.98×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.23×

Profitability

Earnings per share
-$0.31
Return on assets
-79.42%
Return on equity
-294.15%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
2.17×
Quick ratio
2.17×
Cash ratio
2.07×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$44.07M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BMEA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$4.43M$3.62M$3.65M$3.6M$4.2M$4.71M$6.82M$4.83M
Research and development$8.53M$9.14M$9.12M$8.12M$14.4M$16.57M$22.9M$25.24M
Total operating expenses$12.96M$12.77M$12.77M$11.72M$20.81M$21.28M$29.71M$30.07M
Operating income-$12.96M-$12.77M-$12.77M-$11.72M-$20.81M-$21.28M-$29.71M-$30.07M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$6.18M-$8.33M-$12.42M$4.61M-$16.41M-$20.74M-$29.26M-$29.3M
Income taxes$0$0$0$0$0$0$0$0
Net income-$6.18M-$8.33M-$12.42M$4.61M-$16.41M-$20.74M-$29.26M-$29.3M
Net income attributable to common shareholders-$6.18M-$8.33M-$12.42M$4.61M-$16.41M-$20.74M-$29.26M-$29.3M
EBITDA-$12.95M-$12.75M-$12.73M-$11.67M-$18.17M-$20.81M-$29.24M-$29.61M
Basic earnings per share-$0.09-$0.12-$0.17$0.06-$0.27-$0.51-$0.80-$0.81
Diluted earnings per share-$0.09-$0.12-$0.17$0.06-$0.27-$0.51-$0.80-$0.81

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

Biomea Fusion presented clinical and translational data for icovamenib at the ADA 86th Scientific Sessions, demonstrating improvements in HbA1c and C-peptide levels in type 1 and type 2 diabetes patients, along with potential benefits for muscle preservation and fat reduction. The company also expanded its Phase I BMF-650 study to evaluate rapid titration schedules for its oral GLP-1 receptor agonist candidate.

GlobeNewswire Inc.

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

Biomea Fusion reported Q1 2026 net loss of $12.4 million, down significantly from $29.3 million in Q1 2025, driven by reduced R&D and G&A expenses following headcount reductions. The company announced positive 52-week data from its Phase II COVALENT-112 trial showing icovamenib achieved a 52% increase in C-peptide levels in recently diagnosed type 1 diabetes patients with durability through Week 52. Two Phase II type 2 diabetes trials (COVALENT-211 and COVALENT-212) are enrolling with topline data expected in Q4 2026, while the Phase I obesity trial (GLP-131) is on track with initial weight reduction data expected in Q2 2026. Cash runway is projected into Q1 2027.

GlobeNewswire Inc.

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions

Biomea Fusion announced that three abstracts on icovamenib, its investigational oral menin inhibitor, have been selected for late-breaking poster presentations at the ADA 86th Scientific Sessions in June 2026. The presentations will showcase data from Phase 2 trials (COVALENT-111 and COVALENT-112) demonstrating icovamenib's potential to improve beta cell function and insulin secretion in both type 1 and type 2 diabetes patients, including those on background GLP-1 therapy.

GlobeNewswire Inc.

Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

Biomea Fusion announced the first patient dosing in two Phase II clinical trials (COVALENT-211 and COVALENT-212) evaluating icovamenib for type 2 diabetes patients failing standard-of-care therapies. COVALENT-211 targets insulin-deficient T2D patients, while COVALENT-212 targets patients uncontrolled on GLP-1 receptor agonists. Both studies will enroll approximately 60 patients each, with topline 26-week primary endpoint data anticipated in Q4 2026. The trials build on positive Phase II COVALENT-111 data showing durable HbA1c reductions of up to 1.8% that persisted nine months post-treatment.

GlobeNewswire Inc.

Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026

Biomea Fusion announced positive 52-week follow-up results from its Phase II COVALENT-111 study of icovamenib in type 2 diabetes patients. The drug demonstrated durable efficacy nine months post-dosing, with severe insulin-deficient diabetes patients achieving a 1.2% HbA1c reduction at Week 52. The company maintained a favorable safety profile and plans to advance two new Phase II studies targeting specific patient populations.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.